3-[6-chloro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-4-methoxy-benzoic acid | 872513-26-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-[6-chloro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-4-methoxy-benzoic acid
• 英文别名: 3-[6-Chloro-1-(2-trimethylsilylethoxymethyl)pyrazolo[3,4-b]pyridin-3-yl]-4-methoxybenzoic acid
• CAS: 872513-26-3
• 化学式: C₂₀H₂₄ClN₃O₄Si
• 分子量: 433.967
• InChiKey: BRZOTZGTYDNZBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.77
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  86.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3-[6-chloro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-4-methoxy-benzoic acid 在 palladium diacetate (R)-2,2'-bis(diphenylphosphanyl)-1,1'-binaphthyl 、 三苯基膦 、 N,N'-羰基二咪唑 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 0.42h， 生成 4-{3-[6-(2,4-Difluoro-phenylamino)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-4-methoxy-benzoyl}-piperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Pyrazoloheteroaryls: Novel p38α MAP kinase inhibiting scaffolds with oral activity

  摘要：

  A test library with three novel p38 alpha inhibitory scaffolds and a narrow set of substituents was prepared. Appropriate combination of substituent and scaffold generated potent p38 alpha inhibitors, for example, pyrazolo[3,4-b]pyridine 9, pyrazolo[3,4-d]pyrimidine 18a and pyrazolo[3,4-b]pyrazine 23b with potent in vivo activity upon oral administration in animal models of rheumatoid arthritis. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.10.015
• 作为产物：
  描述：

  2,6-二氯吡啶 在 chromium(VI) oxide 、 正丁基锂 、 硫酸 、 双(三甲基硅烷基)氨基钾 、 一水合肼 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 乙醇 、 丙酮 、 正丁醇 为溶剂， 反应 1.0h， 生成 3-[6-chloro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-4-methoxy-benzoic acid
  参考文献：
  名称：

  Pyrazoloheteroaryls: Novel p38α MAP kinase inhibiting scaffolds with oral activity

  摘要：

  A test library with three novel p38 alpha inhibitory scaffolds and a narrow set of substituents was prepared. Appropriate combination of substituent and scaffold generated potent p38 alpha inhibitors, for example, pyrazolo[3,4-b]pyridine 9, pyrazolo[3,4-d]pyrimidine 18a and pyrazolo[3,4-b]pyrazine 23b with potent in vivo activity upon oral administration in animal models of rheumatoid arthritis. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.10.015

文献信息

• WO2006/63820
  申请人：——

  公开号：——

  公开（公告）日：——
• Pyrazoloheteroaryls: Novel p38α MAP kinase inhibiting scaffolds with oral activity
  作者：Laszlo Revesz、Ernst Blum、Franco E. Di Padova、Thomas Buhl、Roland Feifel、Hermann Gram、Peter Hiestand、Ute Manning、Ulf Neumann、Gerard Rucklin

  DOI：10.1016/j.bmcl.2005.10.015

  日期：2006.1

  A test library with three novel p38 alpha inhibitory scaffolds and a narrow set of substituents was prepared. Appropriate combination of substituent and scaffold generated potent p38 alpha inhibitors, for example, pyrazolo[3,4-b]pyridine 9, pyrazolo[3,4-d]pyrimidine 18a and pyrazolo[3,4-b]pyrazine 23b with potent in vivo activity upon oral administration in animal models of rheumatoid arthritis. (c) 2005 Elsevier Ltd. All rights reserved.